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Introduction
The strategy for /Mactam chemotherapy of Staphylococcus aureus infections should be
determined by the mechanisms of bacterial resistance to these agents. Staphylococci have
developed two major defences against /Mactam bacteriostatic and bactericidal effects.
Firstly they may produce penicillinase, which inactivates penicillinase susceptible
molecules such as penicillin, amoxycillin and ampicillin and secondly, they may produce
penicillin-binding protein 2A (PBP 2A), a new low /Mactam affinity PBP which renders
them resistant to methicillin as well as to most other /Mactam antibiotics (Brumfitt &
Hamilton-Miller, 1989; Cookson & Phillips, 1990).
Therapeutic strategies to overcome penicillinase production include (i) penicillinase
resistant /Mactams such as methicillin, nafcillin, and isoxazolyl penicillins (and also first
and second generation cephalosporins) and (ii) penicillinase susceptible antibiotics (such
as amoxycillin and ampicillin) combined with penicillinase inhibitors (Table). Methicillin
resistant S. aureus (MRSA) are less susceptible to /Mactam antibiotics because of the low
affinity PBP2A. Severe MRSA infections are usually treated with non-/Mactam
antibiotics such as vancomycin (Brumfitt & Hamilton, 1989). If a /Mactam is to be effective
against these bacteria, it would have to resist penicillinase hydrolysis and be able to bind
and inhibit PBP 2A, as most MRSA isolates produce both these resistance factors. While
such an ideal drug has yet to be developed, experiments with amoxycillin combined with
the penicillinase inhibitor clavulanate (co-amoxiclav) show that this strategy is effective
(Cantoni et al., 1989; Franciolli et al., 1991; Fluckiger et al., 1992; Entenza et al., 1994).
This review attempts to assess the advantages and disadvantages of co-amoxiclav (or
other penicillin/penicillinase inhibitor combinations) over methicillin or isoxazolyl
penicillins in treatment of S. aureus infections.
Methicillin susceptible S. aureus
Penicillinase producing S. aureus increased dramatically after the introduction of
penicillin in the early forties and now over 80% of S1. aureus isolates produce the enzyme
Phone: + 41 -(21)-3145374; Fax: +41-<21)-3145369.
435
0305-7453/95/030435 + 07 $08.00/0 © 1995 The British Society for Antimicrobial Chemotherapy
436 P. Moreillon
(Gillespie, May & Skurray, 1985; Moellering, 1993). Penicillinase acylates penicillin
molecules in a reaction similar to that of the membrane-bound PBPs involved in cell wall
peptidoglycan synthesis which are the primary targets of /Mactams. However, while
PBP-acyl-penicillin complexes have a long half-life and cause prolonged inhibition of
cell-wall synthesis, penicillinase rapidly hydrolyses its substrate liberating penicillinoic
acid and becomes available to inactivate further /Mactam molecules.
To resist penicillinase degradation, penicillin may be modified by addition of bulky
side-chains which either decrease the enzyme affinity for the drug, or increase the stability
of the penicillin/penicillinase complex (transiently blocking the enzyme), or both
mechanisms may operate (Craig, 1992; Moellering, 1993). Such modifications are the
basis of methicillin, nafcillin, and isoxazolyl penicillins, which have become the gold
standard for treatment of methicillin susceptible staphylococcal infections (Craig, 1992).
Their limitations however include reduced activity against a number of organisms,
including S. aureus. For example, MICs of penicillin G for Streptococcus pyogenes or
Streptococcus pneumoniae are < 0 0 1 mg/L, whereas MICs of methicillin or isoxazolyl
penicillins for these organisms are 4-100 fold greater (Table). Similarly, penicillinase-
negative S. aureus are inhibited by less than 005 mg/L of penicillin G, while 10-50 fold
more methicillin is needed to obtain the same effect. This decrease in intrinsic activity
cannot be overcome by increased drug dosages, as maximum serum concentrations are
similar for penicillin G, amoxycillin and ampicillin and for methicillin or isoxazyl
penicillins (Craig, 1992). Thus, in the absence of penicillinase, 'simple' penicillin G or
amoxycillin may have a 10-50 fold greater therapeutic margin than methicillin or
isoxazolyl penicillins for methicillin susceptible staphylococci. Moreover, penicillin G and
amoxycillin (and also ampicillin) are less bound to plasma proteins than isoxazolyl
penicillins (20-50% and 95%, respectively) (Craig, 1992), a possible advantage at
infection sites with impaired drug diffusion such as cerebrospinal fluid or abscesses.
Therefore, although methicillin and isoxazolyl penicillins are very effective
anti-staphylococcal agents, simpler penicillins might be advantageous if adequately
protected from penicillinase degradation.
Penicillinase inhibitors
Effective protection against penicillinase hydrolysis is conferred by irreversible enzyme
inactivators such as clavulanic acid, sulbactam, and tazobactam (Bush, 1988; Livermore,
1993), which inhibit a number of /Mactamases including staphylococcal penicillinases.
Their /Mactam ring may inhibit bacterial growth at high dosages, but their primary effect
is to protect the partner /Mactam from penicillinase degradation. Such drug combinations
include co-amoxiclav, ticarcillin/clavulanate, ampicillin/sulbactam and piperacilu'n/
tazobactam, which have proved effective in numerous bacterial infections.
Advantages and disadvantages of co-amoxiclav (or similar combinations) in methicillin-
susceptible S. aureus infections
We and others have gained experience in the treatment of both experimental and clinical
staphylococcal infections with co-amoxiclav. The range of MICs for penicillinase-
producing (methicillin sensitive) staphylococci appeared to be lower or equal to that of
methicillin or isoxazolyl penicillins (Table). As expected, co-amoxiclav was also effective
against a number of organisms which were not inhibited by the penicillinase stable
Table. Susceptibilities of staphylococci and streptococci to penicillinase resistant and penicillinase susceptible penicillins
Minimum inhibitory concentrations (mg/L)"
Penicillinase resistant Penicillinase susceptible Combined with clavulanate
Bacteria methicillin isoxa pen* penicillin G amoxycillin penicillin-clavr co-amoxiclav
S. aureus (Meth-S)
Penicillinase positive 1 0-25 >64 >64 s£005 0125
Penicillinase negative 1 0-25 «£005 <0-125 <005 0125
S. aureus (Meth-R)
Penicillinase positive >64 32 >64 >64 4-8 8
Penicillinase negative >64 32 4 8 4 8
Streptococci
S.pneumoniae 01 005 001 002 ND 002
S.pyogenes 0-2 002 0005 001 ND 001
"Data compiled from author's own observations and data presented by Craig (1992). Note that MICs of nafcillin (not reported in the Table) are
approximately similar to those of isoxazolyl penicillins.
'Isoxazolyl penicillins include oxacillin, cloxacillin, dicloxacillin and flucloxacillin.
'Penicillin MICs were performed in the presence of a concentration of 4 mg/L clavulanate.
ND, Not determined.
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derivatives, such as Gram-negative and anaerobic bacteria. High tissue concentrations
of both components may be achieved after either oral or parenteral administration
(Munch, Blaser & Siegenthaler, 1981; Weismeier et al., 1989). Good in-vitro
anti-staphylococcal activity is reflected in efficacy in vivo, as shown in the experimental
model of endocarditis (Cantoni etal., 1989; Franciolli etal., 1991; Fluckigere/a/., 1992;
Entenza et al., 1994) as well as clinically (Fleisher, Wilmott & Campos, 1983; Camacho
et al., 1992; Powers, 1993; Tassler, 1993; Moreillon, 1994). Good results have been
obtained with ampicillin/sulbactam in children with staphylococcal skeletal infections
(Aronoffe/ al., 1986; Loffler et al., 1986). On the basis of such results co-amoxiclav has
been used for empirical treatment of infections which might involve S. aureus (Goldstein
etal., 1987; Bass etal., 1993; Moreillon, 1994). It is noteworthy that none of these clinical
studies directly compared co-amoxiclav (or similar drug combinations) with methicillin
or isoxazolyl penicillins in staphylococcal disease but assessed the efficacy of
combinations in a number of clinical infections, many due to staphylococci. Therefore,
it is unclear whether co-amoxiclav or similar combinations have any advantage over
methicillin or isoxazolyl penicillins and there is a need for further comparative studies.
The potential advantages of co-amoxiclav (or similar combinations) can be summarised
as follows, (i) If adequately protected from bacterial penicillinase, simpler penicillin
molecules might be more effective than methicillin or isoxazolyl penicillins against
methicillin sensitive S. aureus. This is well established for penicillin G in vitro and also
tends to be true for amoxycillin and ampicillin (Table). Since agents with lower MICs
might be therapeutically more effective, it seems important to compare the efficacy of
combination therapy with methicillin or isoxazolyl penicillins in deep-seated
staphylococcal infections, (ii) Penicillin G and its amino-derivatives amoxycillin and
ampicillin are also active against a variety of other bacteria which may coexist at sites
of infection and are not adequately covered by methicillin or isoxazolyl penicillins. This
makes co-amoxiclav (and also ampicillin/sulbactam) suitable for empirical treatment of
infections which might include S. aureus and would not respond to methicillin or
isoxazolyl penicillins alone, (iii) Co-amoxiclav is generally well tolerated and has greater
bioavailability than methicillin or isoxazolyl penicillins, (iv) Finally, co-amoxiclav is
cheaper than isoxazolyl penicillins (there is a price difference of about 20% between these
compounds in Switzerland).
The disadvantage of co-amoxiclav is that broad spectrum therapy is best avoided once
a specific pathogen has been identified. Over-use of broad spectrum antibacterial agents
promotes selection of drug resistance in normal gut flora, and in common with many other
physicians, we treat penicillinase-producing (methicillin susceptible) S. aureus with
isoxazolyl penicillins. In order to outweigh its 'broad spectrum' disadvantage,
co-amoxiclav should demonstrate significantly superior anti-staphylococcal activity
compared with methicillin or isoxazolyl penicillins in vivo. Whether such an advantage
exists remains to be determined by valid comparative studies.
A simpler alternative to this dilemma would be to combine clavulanate (or other
penicillinase inhibitors) with penicillin G. Penicillin G has excellent intrinsic activity
against penicillinase-nega/we S. aureus and is the first choice antibiotic in this now
unusual situation. In addition, penicillin G has a much narrower antibacterial spectrum
than its amino-derivatives amoxycillin or ampicillin. Therefore, combination of penicillin
G with penicillinase inhibitors might emerge as the best antibacterial combination for
treating methicillin susceptible staphylococcal infections. Unfortunately this combi-
nation is not yet available and manufacturers should consider such a formulation.
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Methicillin resistant S. aureus (MRSA)
Methicillin resistant (PBP 2A-producing) staphylococci emerged in the sixties, in
response to the introduction of new penicillinase stable /Mactams such as methicillin
(Brumfitt & Hamilton-Miller, 1990). The initial increase in MRSA was relatively slow,
perhaps because the PBP 2A (mec) gene is chromosomal and less transmissible than
penicillinase genes, which reside on transferable plasmids or transposons. Nevertheless,
MRSA has steadily increased over the last decade and now represents up to 40% of
staphylococcal isolates in certain hospitals worldwide. Moreover, MRSA are also
resistant to most other antibiotics, posing a challenge to modern antimicrobial
chemotherapy (Brumfitt & Hamilton-Miller, 1989; Cookson & Phillips, 1990).
Interestingly, traditional /Mactams such as penicillin G, amoxycillin and ampicillin
have relatively good PBP 2A affinity and also relatively low MICs for penicillinase
negative MRSA isolates (Table) (Chambers & Sachdeva, 1990; Franciolli et al., 1881).
These antibiotics must be combined with penicillinase inhibitors to avoid degradation by
penicillinase producers. Co-amoxiclav and ampicillin/sulbactam appeared to fulfil these
conditions both in vitro and in vivo, as shown in the experimental model of endocarditis
and in preliminary human studies. In animals, amoxycillin alone cured experimental
endocarditis due to penicillinase negative MRSA, whereas cloxacillin was ineffective
(Franciolli et al., 1991). Amoxycillin alone failed against penicillinase producing parent
strains as it was hydrolysed by bacterial /J-lactamases. However, efficacy could be fully
restored by combining amoxycillin with clavulanate. These experimental results were
confirmed using other MRSA isolates (which expressed both 'heterogeneous' and
'homogeneous' resistance to methicillin) as well as with methicillin resistant S. epidermidis
(Entenza et al., 1994) and also using ampicillin/sulbactam (Hirano & Bayer, 1991 and
unpublished observation).
Two preliminary reports have suggested that co-amoxiclav and ampicillin/sulbactam
might be effective clinically against MRSA infections (Andreoni et al., 1991; Nicolas,
Kitzis & Karim, 1993). In a pilot study, Andreoni et al. (1991) treated 19 patients with
methicillin resistant staphylococcal skin and soft tissue infections (15 due to MRSA) with
high parenteral doses (9-12 g/day) of ampicillin/sulbactam for 9-25 days. Clinical and
bacteriological responses were excellent and organisms were eradicated in 89% of cases.
In another study, Nicolas et al. (1993) successfully treated 14/17 urinary tract infections
due to MRSA (in urology patients) with oral co-amoxiclav. While this success was related
to the high urinary concentration of the drug, it suggests that these combinations can be
effective against some MRSA infections.
It is noteworthy however that these were uncontrolled pilot studies undertaken without
comparison with standard anti-MRSA drugs such as vancomycin and /Mactam treatment
of MRSA is not currently advocated, at least until these results are confirmed by
comparative studies.
Conclusion
These experimental and clinical data demonstrate that co-amoxiclav or similar drug
combinations (such as ampicillin/sulbactam) are effective against methicillin susceptible
S. aureus. In addition, these antibiotics could perhaps also be effective therapy for certain
methicillin resistant staphylococcal infections. The broad antibacterial spectrum and
anti-staphylococcal activity of co-amoxiclav make it suitable for empirical therapy of
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infections which may involve staphylococci. However, the possible role of co-amoxiclav
in preference to methicillin or isoxazolyl penicillins for long term therapy of methicillin
susceptible staphylococci remains uncertain because there are as yet no comparative
clinical studies to resolve the issue.
Such studies would be worthwhile because co-amoxiclav (and also ampicillin/sulbac-
tam) may be more active than methicillin or isoxazolyl penicillins against staphylococci
and also have better bioavailability. An even better choice would be penicillin G combined
with a penicillinase inhibitor, because it would have a narrower antibacterial spectrum
and be more active than co-amoxiclav against staphylococci. Finally, further studies to
compare the efficacy of high dose co-amoxiclav (or ampicillin/sulbactam) with standard
anti-MRSA therapy would be worth considering initially in non-life-threatening
infections. In view of the therapeutic problems posed by these organisms today, these are
potentially important investigations.
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